Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuwellis ( (NUWE) ) just unveiled an announcement.
On January 21, 2026, Nuwellis implemented significant changes to its board of directors, with Dave McDonald, Mike McCormick and Dr. Maria Costanzo resigning—departures the company said were not due to any disagreements over operations, policies or practices—prompting a reduction in board size from six to five members. Effective the same day, the company appointed iSpecimen CEO Katharyn Field and investment manager Mika Grasso as independent Class I directors, assigning them to key committees and making them eligible for standard director compensation and indemnification; both have agreed to resign if a planned equity investment of at least $5 million does not materialize within a specified period following the filing and clearance of a related registration statement, underscoring the close linkage between the refreshed board composition and Nuwellis’s near-term capital-raising efforts.
The most recent analyst rating on (NUWE) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
The score is held down primarily by weak financial performance (sharp TTM revenue decline, large ongoing losses, and continued negative free cash flow). Technicals also remain bearish with price below key moving averages and negative MACD. Valuation provides little support given the company is loss-making and no dividend yield is provided.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a Minneapolis-based medical technology company focused on advancing precision fluid management technologies for cardiorenal care across acute and chronic settings. Its portfolio, including the Aquadex SmartFlow system for managing fluid overload in adult and pediatric patients, is aimed at supporting monitoring, therapy and data-informed clinical decision-making in complex cardiorenal conditions.
Average Trading Volume: 98,540
Technical Sentiment Signal: Sell
Current Market Cap: $3.04M
See more data about NUWE stock on TipRanks’ Stock Analysis page.